Cargando…
Epitope-Specific Immunotherapy Targeting CD4-Positive T Cells in Celiac Disease: Safety, Pharmacokinetics, and Effects on Intestinal Histology and Plasma Cytokines with Escalating Dose Regimens of Nexvax2 in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study
BACKGROUND: Nexvax2® is a novel, peptide-based, epitope-specific immunotherapy intended to be administered by regular injections at dose levels that increase the threshold for clinical reactivity to natural exposure to gluten and ultimately restore tolerance to gluten in patients with celiac disease...
Autores principales: | Daveson, A. James M., Ee, Hooi C., Andrews, Jane M., King, Timothy, Goldstein, Kaela E., Dzuris, John L., MacDougall, James A., Williams, Leslie J., Treohan, Anita, Cooreman, Michael P., Anderson, Robert P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5832635/ https://www.ncbi.nlm.nih.gov/pubmed/29191561 http://dx.doi.org/10.1016/j.ebiom.2017.11.018 |
Ejemplares similares
-
A Sensitive Whole Blood Assay Detects Antigen-Stimulated Cytokine Release From CD4+ T Cells and Facilitates Immunomonitoring in a Phase 2 Clinical Trial of Nexvax2 in Coeliac Disease
por: Hardy, Melinda Y., et al.
Publicado: (2021) -
Cytokine release and gastrointestinal symptoms after gluten challenge in celiac disease
por: Goel, Gautam, et al.
Publicado: (2019) -
Prediction of celiac disease associated epitopes and motifs in a protein
por: Tomer, Ritu, et al.
Publicado: (2023) -
Clinical and Histologic Mimickers of Celiac Disease
por: Kamboj, Amrit K, et al.
Publicado: (2017) -
Suppression of Inflammatory Immune Responses in Celiac Disease by Experimental Hookworm Infection
por: McSorley, Henry J., et al.
Publicado: (2011)